Last reviewed · How we verify

Benzamycin (Erythromycin Lactobionate)

Pfizer · FDA-approved approved Small molecule Quality 65/100

Benzamycin (Erythromycin Lactobionate) is a macrolide antibiotic developed by Arbor Pharmas LLC and currently owned by Hospira. It targets the potassium voltage-gated channel subfamily H member 2 and is used to treat various bacterial infections, including acne, sinusitis, and pneumonia. Benzamycin is a small molecule modality that has been FDA-approved since 1964 and is now off-patent with multiple generic manufacturers. It has a relatively short half-life of 2.0 hours and bioavailability of 35%. As an off-patent medication, Benzamycin is widely available in the market.

At a glance

Generic nameErythromycin Lactobionate
SponsorPfizer
Drug classMacrolide
TargetPotassium voltage-gated channel subfamily H member 2
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved
First approval1964

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results